Skip to content

Potential New Treatment for Metastatic Lung Cancer

Search Clinical Trials

Trial Objectives


Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet current treatment options are limited. In fact, the standard treatment for metastatic NSCLC has a low 5-year survival rate.

Researchers want to know if an investigational drug called SAR408701 is better than docetaxel, a chemotherapy drug already approved to treat non-small cell lung cancer (NSCLC) patients with CEACAM 5 positive tumors. The goal of this study is to determine if SAR408701 improves survival rate for NSCLC patients.

Over the course of the study, participants will have 1-2 clinic visits each month where they will receive physical exams to evaluate their response to either SAR408701 or docetaxel and monitor disease progression. Data gathered will allow researchers to track improvements in disease response, quality of life and overall symptoms to determine the effectiveness of the new drug.

Who Can Participate


Adults aged 18 years and older being treated at National Jewish Health for non-small cell lung cancer, who have progressive disease during or after at least 2 cycles of platinum-based chemotherapy and an immune checkpoint inhibitor.

Age: 18+ Gender Any

Estimated Time Commitment


1 year

Payment & Reimbursement


Payment Not Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Kris Eliopoulos
303.270.2622

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Sanofi

Principal Investigators

Laurie L. Carr

Laurie L. Carr, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required